Passage Bio Inc (PASG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Passage Bio Inc (PASG) has a cash flow conversion efficiency ratio of -1.105x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.99 Million) by net assets ($11.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PASG market cap overview for the company's overall valuation and market capitalisation.
Passage Bio Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Passage Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Passage Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Passage Bio Inc ranked by their cash flow conversion efficiency. See PASG operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samil Co.Ltd
KQ:032280
|
0.015x |
|
Ambitions Enterprise Management Co. L.L.C Class A Ordinary Shares
NASDAQ:AHMA
|
0.032x |
|
NSX Ltd
AU:NSX
|
0.587x |
|
Nextedia
PA:ALNXT
|
-0.050x |
|
Blue Sky Uranium Corp
V:BSK
|
0.825x |
|
EDGE TOTAL INTELLIGENCE
F:Q5I
|
0.330x |
|
Quantum Software SA
WAR:QNT
|
0.009x |
|
Jocil Limited
NSE:JOCIL
|
-0.200x |
Annual Cash Flow Conversion Efficiency for Passage Bio Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Passage Bio Inc from 2018 to 2025. View Passage Bio Inc (PASG) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.75 Million | $-31.51 Million | -1.680x | -114.61% |
| 2024-12-31 | $61.26 Million | $-47.96 Million | -0.783x | -11.31% |
| 2023-12-31 | $111.28 Million | $-78.26 Million | -0.703x | -19.80% |
| 2022-12-31 | $201.37 Million | $-118.21 Million | -0.587x | -47.44% |
| 2021-12-31 | $318.66 Million | $-126.88 Million | -0.398x | -50.68% |
| 2020-12-31 | $304.71 Million | $-80.52 Million | -0.264x | -15.48% |
| 2019-12-31 | $174.35 Million | $-39.90 Million | -0.229x | -115.00% |
| 2018-12-31 | $-12.17 Million | $-18.57 Million | 1.525x | -- |
About Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops P… Read more